IL258464A - Pharmaceutical compositions for oral administration of peptide drugs - Google Patents
Pharmaceutical compositions for oral administration of peptide drugsInfo
- Publication number
- IL258464A IL258464A IL258464A IL25846418A IL258464A IL 258464 A IL258464 A IL 258464A IL 258464 A IL258464 A IL 258464A IL 25846418 A IL25846418 A IL 25846418A IL 258464 A IL258464 A IL 258464A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical formulations
- oral delivery
- peptide drugs
- peptide
- drugs
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15188838 | 2015-10-07 | ||
| PCT/EP2016/074110 WO2017060500A1 (en) | 2015-10-07 | 2016-10-07 | Pharmaceutical formulations for the oral delivery of peptide drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL258464A true IL258464A (en) | 2018-05-31 |
Family
ID=54292636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL258464A IL258464A (en) | 2015-10-07 | 2018-03-29 | Pharmaceutical compositions for oral administration of peptide drugs |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10905744B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3359181A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018529749A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108135962A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016335287A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2997343A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL258464A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017060500A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| AU2012241894B2 (en) | 2011-04-12 | 2015-12-03 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| ES2715308T3 (es) | 2012-03-22 | 2019-06-03 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y su preparación |
| KR102072202B1 (ko) | 2012-03-22 | 2020-01-31 | 노보 노르디스크 에이/에스 | Glp-1 펩티드의 조성물 및 그것의 제조 |
| WO2013189988A1 (en) | 2012-06-20 | 2013-12-27 | Novo Nordisk A/S | Tablet formulation comprising a peptide and a delivery agent |
| RS58039B1 (sr) | 2013-05-02 | 2019-02-28 | Novo Nordisk As | Oralno doziranje glp-1 jedinjenja |
| HRP20211127T1 (hr) * | 2015-10-09 | 2021-10-15 | Radius Health, Inc. | Formulacije analoga pthrp, njihovi transdermalni flasteri, i njihova uporaba |
| ES2904891T3 (es) | 2016-04-18 | 2022-04-06 | Radius Health Inc | Formulaciones de abaloparatida, parche transdérmico de la misma y usos de la misma |
| CN109381695A (zh) * | 2017-08-09 | 2019-02-26 | 武汉武药科技有限公司 | 一种门冬氨酸帕瑞肽注射液及其制备方法和用途 |
| TWI751379B (zh) * | 2017-09-21 | 2022-01-01 | 奧孟亞股份有限公司 | 用於遞送胜肽之藥物組合物 |
| AR114353A1 (es) * | 2018-02-02 | 2020-08-26 | Novo Nordisk As | Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico |
| US20210087250A1 (en) * | 2018-04-06 | 2021-03-25 | Cyprumed Gmbh | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| CA3102509A1 (en) * | 2018-06-10 | 2019-12-19 | Zim Laboratories Limited | Oral mucosal delivery systems comprising monophasic concentrate of teriparatide |
| GB201813678D0 (en) * | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
| JP7480132B2 (ja) * | 2018-10-12 | 2024-05-09 | アドヴァンスド アクセラレーター アプリケーションズ インターナショナル エセ.アー. | 放射性標識されたgprpアンタゴニスト及び界面活性剤を含む医薬組成物 |
| WO2020180534A1 (en) | 2019-03-01 | 2020-09-10 | President And Fellows Of Harvard College | Methods and compositions for protein delivery |
| WO2020183318A1 (en) * | 2019-03-08 | 2020-09-17 | Anya Biopharm Inc. | Oral formulation and treatment of pth analog. |
| CN111714643A (zh) * | 2019-03-22 | 2020-09-29 | 约翰霍普金斯大学 | 一种单宁酸/Fe3+纳米颗粒体系、药物递送方法 |
| GB201906917D0 (en) * | 2019-05-16 | 2019-07-03 | Intract Pharma Ltd | Novel compositions |
| CN112057619A (zh) * | 2019-06-10 | 2020-12-11 | 苏州兰鼎生物制药有限公司 | 一种具有降血糖作用的药物组合物 |
| CN115209910A (zh) * | 2020-03-18 | 2022-10-18 | 四川海思科制药有限公司 | 口服药物组合物 |
| US20210315930A1 (en) * | 2020-04-14 | 2021-10-14 | David A. Cuddeback | Nutraceutical composition for multimodal prophylaxis against and treatment of viral and bacterial infection and inflammation |
| CN114272511B (zh) * | 2021-01-12 | 2023-08-01 | 广州新济药业科技有限公司 | 司美格鲁肽可溶性微针贴片及其制备方法 |
| FR3120189B1 (fr) | 2021-03-01 | 2024-11-29 | Farid Bennis | Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1 |
| CN113117050B (zh) * | 2021-05-06 | 2022-04-26 | 合肥天汇孵化科技有限公司 | 多肽组合物及其用途 |
| CA3237751A1 (en) | 2021-11-10 | 2023-05-19 | Tyler Brown | Ionic liquid compositions |
| WO2024043867A1 (en) * | 2022-08-20 | 2024-02-29 | Sinapu Llc | C60 histidine carnosine fumarates and use |
| CN115321657B (zh) * | 2022-08-31 | 2023-10-03 | 四川农业大学 | 一种疏水壳聚糖-聚合氯化铝Hmcs-PAC复合絮凝剂及其制备与应用 |
| WO2024077409A1 (en) * | 2022-10-09 | 2024-04-18 | Guangzhou Dazhou Biomedicine Ltd. | Oral delivery of therapeutic agents |
| US20260007869A1 (en) | 2023-06-23 | 2026-01-08 | Vaxess Technologies, Inc. | Microneedle array patches (maps), systems, and methods for manufacturing and using same |
| WO2025046590A1 (en) * | 2023-08-30 | 2025-03-06 | Entera Bio Ltd. | Formulations for oral administration of active agents |
| US12377156B2 (en) * | 2023-10-24 | 2025-08-05 | Neuvian Ip Holdings, Llc | Compositions and methods for treatment of wounds and inflammatory skin conditions |
| US20250235509A1 (en) * | 2024-01-23 | 2025-07-24 | Men Hwei Tsai | Formulation and Method of Preparing Glucagon-like Peptide-1 (GLP-1) for Oral Administration |
| WO2025188317A1 (en) * | 2024-03-08 | 2025-09-12 | Neuvian Skincare Llc | Compositions and methods for hair treatment |
| US12409204B1 (en) | 2024-03-08 | 2025-09-09 | Neuvian Ip Holdings, Llc | Compositions and methods for hair treatment |
| CN122376711A (zh) * | 2024-06-03 | 2026-07-14 | 深圳奥礼生物科技有限公司 | 口服的多肽组合物 |
| CN122251618A (zh) * | 2026-05-27 | 2026-06-23 | 浙江大学 | 一种钙离子或硼酸酯键桥联的阳离子基多肽口服递送系统 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
| US5661130A (en) | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| CN1228708A (zh) | 1996-09-04 | 1999-09-15 | 有限会社多特 | 经口给药用含肽药物组合物 |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| EP1060191B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
| AU3247799A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| AU2610899A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
| DE69916811T2 (de) | 1998-02-27 | 2005-04-14 | Novo Nordisk A/S | Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden |
| NZ534409A (en) | 1999-04-05 | 2006-03-31 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| BR0107764A (pt) | 2000-01-20 | 2002-11-12 | Basilea Pharmaceutica Ag | Composições de peptìdeo cìclico nasalmente administráveis |
| US6248360B1 (en) | 2000-06-21 | 2001-06-19 | International Health Management Associates, Inc. | Complexes to improve oral absorption of poorly absorbable antibiotics |
| WO2003007913A2 (en) | 2001-07-20 | 2003-01-30 | Samir Mitragotri | Method for oral drug delivery |
| IL161446A0 (en) | 2001-11-26 | 2004-09-27 | Daiichi Suntory Pharma Co Ltd | Medicinal compositions for nasal absorption |
| WO2004024225A1 (en) | 2002-09-16 | 2004-03-25 | Zicam, Llc. | System and method for delivering a composition to the nasal membrane |
| EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| CN101665538A (zh) | 2003-12-18 | 2010-03-10 | 诺沃挪第克公司 | 与白蛋白样物质相连的新glp-1类似物 |
| JP2007537141A (ja) | 2003-12-18 | 2007-12-20 | ノボ ノルディスク アクティーゼルスカブ | 新規なglp−1化合物 |
| WO2005080489A1 (fr) | 2004-02-23 | 2005-09-01 | Caiteng Zhang | Solution de chelate(s) metal/polymere et leurs utilisations |
| ES2542228T3 (es) | 2004-07-08 | 2015-08-03 | Novo Nordisk A/S | Marcas de prolongación polipeptídica que comprenden un resto de tetrazol |
| JP2006028031A (ja) | 2004-07-12 | 2006-02-02 | Ltt Bio-Pharma Co Ltd | 経粘膜吸収用薬物封入ナノ粒子 |
| CN101027318B (zh) | 2004-07-19 | 2016-05-25 | 比奥孔有限公司 | 胰岛素-低聚物共轭物,制剂及其用途 |
| US20060078623A1 (en) | 2004-08-13 | 2006-04-13 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| CA2578748C (en) | 2004-09-03 | 2014-10-14 | Kyowa Hakko Kogyo Co., Ltd. | Composition and method for prevention or treatment of stomatitis |
| JP5107713B2 (ja) | 2004-10-07 | 2012-12-26 | ノヴォ ノルディスク アー/エス | 遅延性のエキセンディン−4化合物 |
| JP2008515856A (ja) | 2004-10-07 | 2008-05-15 | ノボ ノルディスク アクティーゼルスカブ | 遅延性glp−1化合物 |
| ES2484796T3 (es) | 2005-03-18 | 2014-08-12 | Novo Nordisk A/S | Compuestos de GLP-1 extendidos |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| WO2007025332A1 (en) | 2005-08-29 | 2007-03-08 | Dia-B Tech Limited | A peptide and zinc ion composition for treating diabetes and enhancing immune function |
| EP2722054B1 (en) | 2005-09-06 | 2018-03-21 | Oramed Pharmaceuticals Inc. | Methods and compositions for oral administration of proteins |
| US20070086952A1 (en) | 2005-09-29 | 2007-04-19 | Biodel, Inc. | Rapid Acting and Prolonged Acting Inhalable Insulin Preparations |
| US20090214657A1 (en) | 2005-11-30 | 2009-08-27 | Muhammad Waseem Tahir Qazi | Orally Absorbed Pharmaceutical Formulation and Method of Administration |
| US20090318353A1 (en) | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
| US20100261637A1 (en) | 2007-09-05 | 2010-10-14 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| US20100292133A1 (en) | 2007-09-05 | 2010-11-18 | Novo Nordisk A/S | Truncated glp-1 derivaties and their therapeutical use |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| RS60101B1 (sr) | 2008-08-15 | 2020-05-29 | Ironwood Pharmaceuticals Inc | Formulacije koje sadrže linaklotid za oralnu primenu |
| AU2010250452B2 (en) | 2009-05-20 | 2014-06-05 | Toray Industries, Inc. | Cell membrane-permeable peptides |
| WO2011019819A1 (en) | 2009-08-12 | 2011-02-17 | Forest Laboratories Holdings Limited | Orally disintegrating compositions of linaclotide |
| US8748573B2 (en) | 2009-08-06 | 2014-06-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
| CN102596253B (zh) | 2009-09-30 | 2013-11-06 | 蒂奥迈里克斯研究与指导有限公司 | 含有维生素b 亚结构的粘膜粘着聚合物 |
| WO2011116139A2 (en) | 2010-03-16 | 2011-09-22 | Chiasma Inc. | Improved pharmaceutical compositions and methods of delivery |
| KR20130100897A (ko) | 2010-04-21 | 2013-09-12 | 나노메가 메디컬 코포레이션 | 나노입자의 약제학적 조성물 |
| WO2012112319A1 (en) | 2011-02-04 | 2012-08-23 | Aegis Therapeutics, Llc | Orally bioavailable peptide drug compositions and methods thereof |
| CN103458873B (zh) | 2011-04-14 | 2016-04-13 | 诺沃—诺迪斯克有限公司 | 用于口服肽递送的脂肪酸酰化的氨基酸 |
| WO2012170828A1 (en) | 2011-06-10 | 2012-12-13 | Monosol Rx, Llc | Combination peptide-nanoparticles and delivery systems incorporating same |
| US20130004590A1 (en) * | 2011-06-28 | 2013-01-03 | Lin Connie B | Zinc oxide/acid containing compositions and methods for treating and/or preventing enzymatic irritation |
| KR102072202B1 (ko) | 2012-03-22 | 2020-01-31 | 노보 노르디스크 에이/에스 | Glp-1 펩티드의 조성물 및 그것의 제조 |
| CA2872314C (en) | 2012-05-03 | 2021-08-31 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| US20150174076A1 (en) | 2012-06-14 | 2015-06-25 | Entrega, Inc. | Mucoadhesive devices for delivery of active agents |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
| JP2017525656A (ja) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー/エス | 医療用のglp−1/グルカゴン受容体コアゴニスト |
| DK3006045T3 (en) * | 2014-10-07 | 2017-07-17 | Cyprumed Gmbh | Pharmaceutical formulations for oral administration of peptide or protein drugs |
| WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
-
2016
- 2016-10-07 EP EP16779074.0A patent/EP3359181A1/en not_active Withdrawn
- 2016-10-07 CN CN201680057777.9A patent/CN108135962A/zh active Pending
- 2016-10-07 WO PCT/EP2016/074110 patent/WO2017060500A1/en not_active Ceased
- 2016-10-07 US US15/766,546 patent/US10905744B2/en active Active
- 2016-10-07 JP JP2018517702A patent/JP2018529749A/ja active Pending
- 2016-10-07 CA CA2997343A patent/CA2997343A1/en not_active Abandoned
- 2016-10-07 AU AU2016335287A patent/AU2016335287A1/en not_active Abandoned
-
2018
- 2018-03-29 IL IL258464A patent/IL258464A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN108135962A (zh) | 2018-06-08 |
| US20180280481A1 (en) | 2018-10-04 |
| AU2016335287A1 (en) | 2018-04-12 |
| JP2018529749A (ja) | 2018-10-11 |
| US10905744B2 (en) | 2021-02-02 |
| CA2997343A1 (en) | 2017-04-13 |
| EP3359181A1 (en) | 2018-08-15 |
| WO2017060500A1 (en) | 2017-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251462A0 (en) | Pharmaceutical formulations for oral administration of peptide or protein drugs | |
| IL275220A (en) | Oral administration of active drug substances | |
| GB201620066D0 (en) | Solid Pharmaceutical dosage formulations and processes | |
| PL3224254T3 (pl) | Podstawione indazole, sposób ich wytwarzania, preparaty farmaceutyczne je zawierające, oraz ich zastosowanie do wytwarzania leków | |
| ZA201903101B (en) | Pharmaceutical formulations | |
| IL273740A (en) | Oral pharmaceutical formulation containing bacteria | |
| HUP1700253A1 (hu) | Szilárd orális gyógyszerkészítmények | |
| IL279127A (en) | Dispensing devices for drug administration | |
| IL273451A (en) | Pharmaceutical preparations for administration of peptides | |
| ZA201800470B (en) | An oral pharmaceutical dosage form for the delivery of a peptide and/or protein | |
| ZA201703562B (en) | Pharmaceutical composition for oral administration comprising taxane | |
| ZA202006570B (en) | Pharmaceutical formulations | |
| SMT202300074T1 (it) | Composizione farmaceutica stabile per somministrazione orale | |
| EP3290037A4 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | |
| IL262204A (en) | Granular formulation for oral administration | |
| EP3346996A4 (en) | ORAL PHARMACEUTICAL PHARMACEUTICAL FORM OF BUDESONID | |
| SG11202010792TA (en) | Improved pharmaceutical formulations | |
| IL279128A (en) | Dispensing devices for drug administration | |
| IL252080B (en) | Oral administration of drugs that are unstable or poorly absorbed | |
| SG11202104499RA (en) | Pharmaceutical formulations for subcutaneous administration | |
| IL271908A (en) | Over-compressed pharmaceutical preparations | |
| PT3650024T (pt) | Composição farmacêutica para administração nasal compreendendo rifampicinas para tratar demência | |
| EP3162368A4 (en) | Pharmaceutical composition for oral administration | |
| SG11202101547WA (en) | Pharmaceutical composition for oral administration | |
| EP3880171C0 (en) | IBUPROFEN CONTAINING ORAL PHARMACEUTICAL FORMULATION |